Prospect News: News for Invitrogen Corp.

E-mail us: service@prospectnews.com Or call: 212 374 2800

Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products

Add to balance / Manage account

Not logged in

Prospect News home > Main news index > All issuers starting with I > Issuers starting with I, CV only > All stories on Invitrogen Corp. > Stories on Invitrogen Corp., CV only

Search again

Enter part or all of the issuer name:

Market:

All markets No structured products Bank loans Canadian bonds CLOs Convertibles Distressed debt Emerging markets High yield Investment grade Liability management Municipals PIPEs Preferreds Private placements All leveraged markets Structured products

Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each. All others are $1.00 each. Headlines in gray are not currently covered by your subscription.

Invitrogen Corp.

11/10/2009	CV	Life Technologies 2% convertible senior notes convertible to Dec. 31
9/8/2008	CVIG	Fitch: Invitrogen supported
8/4/2008	CVIG	Fitch gives Invitrogen, convertibles BBB-
7/23/2008	CVIG	S&P rates Invitrogen BBB-
6/12/2008	CV	Market Commentary: KeyCorp deal eyed ahead of pricing; Lehman active; Coors slips on rival's buyout news; Invitrogen in line
2/20/2008	CV	Market Commentary: Convertibles thinly traded amid weaker tone; Suntech, Level 3 lower; Encysive surges
10/30/2006	CV	Market Commentary: Level 3 gains on takeout rumors; Medis quiet amid borrow concerns; Invitrogen, Red Hat gain slightly
10/27/2006	CV	Market Commentary: Wesco gains, Kemet quiet on debut; FiberTower keeps rising; Red Hat higher on buyback; Invitrogen slips
8/4/2006	CV	Market Commentary: Scottish Re stays high; Reckson rides counter-bid rumors; Invitrogen shrugs off miss; PDL gains in line
12/5/2005	BTCV	Invitrogen buys back $100 million 2.25% convertibles
12/1/2005	CV	Market Commentary: Platinum debut has shine; Calpine trades mixed; XL Capital, Ceradyne launch new deals
10/28/2005	CV	Market Commentary: Invitrogen drops, but gains on hedge; Amkor steadies after fall; Nektar weaker
10/25/2005	CV	Market Commentary: Sovereign slides, Schlumberger, Sepracor lift; Essex reoffered at 98; Flextronics drops after close
9/12/2005	CV	Market Commentary: Northwest drops as other airline convertibles trade mixed; software names see better bids
7/19/2005	CV	Market Commentary: Convertibles market sees strength in airlines, energy, as biotechs weaken; Lucent falls, but Lowe's gains
6/24/2005	CV	Market Commentary: Convertibles mostly extend losses a second day; biotechs waver, but some energy issues see more gains
6/23/2005	CV	Market Commentary: Convertibles market trades mostly lower, but some energy issues climb with oil prices
6/21/2005	CV	Market Commentary: Convertible players eye REIT new issues; Calpine, airline issues lift in pockets of trading
6/21/2005	CV	Market Commentary: Convertible players eye REIT new issues; Calpine, airline issues lift in pockets of trading
6/17/2005	CV	Market Commentary: Convertibles quiet after week's new issues flurry; airlines drift lower; Ford slips as GM edges higher
6/16/2005	CV	Market Commentary: Large MetLife issue takes center stage; Transocean rises with higher oil prices; GM sags
6/16/2005	BTCV	Invitrogen greenshoe exercised, bringing convertible offering to $350 million
6/15/2005	BTCV	New Issue: Invitrogen sells upsized $325 million convertibles to yield 3.25%, up 27.5%
6/15/2005	CV	Market Commentary: Convertibles catch wave of optimism as new Invitrogen deal gains favor; Saks sinks after default notice
6/14/2005	CV	Market Commentary: Convertibles see more selling ahead of June redemptions; GM, Ford higher, but Calpine, Northwest sink
6/13/2005	CV	Market Commentary: Invitrogen launches $300 million convertible; Connetics, Cephalon stir market; Northwest hits turbulence
6/13/2005	BTCV	Invitrogen launches $300 million convertibles talked at 2.75%-3.25%, up 27.5%-32.5%
5/6/2005	CV	Invitrogen buys back $125 million 21/4% convertibles
4/28/2005	CV	Market Commentary: BearingPoint believers step up; Calpine sell-off gathering steam; Deutsche Telekom convertibles ease
12/9/2004	CV	Invitrogen completes exchange for 1.5%, 2% convertibles
11/9/2004	CV	Invitrogen starts exchange for 1.5%, 2% convertibles in response to new accounting rules
7/21/2004	CV	Market Commentary: Ocwen getting large outright orders; Lucent, telecom zeal fades; Delta skids off highs
4/27/2004	CV	Market Commentary: Reebok bounces to 102.25; OSI Pharma, cancer issues snap back; three deals at bat
2/13/2004	CV	New Issue: Invitrogen $450 million convertible yield 1.5%, up 32.5%
2/13/2004	CV	Market Commentary: Adelphia bonds Earthbound, lose 6 points; Sirius, new paper active but slip to below par levels
2/12/2004	CV	Invitrogen $450 million quick-sale convertible talked at 1.25-1.75% yield, 30-35% premium
2/12/2004	CV	Market Commentary: Buyers propel new AMR convert; Bristol-Myers up on Erbitux news; Incyte trades at par in gray market
12/24/2003	CV	Market Commentary: CKE, Triarc convertibles feel the bite from mad cow scare; Invitrogen shoots up on merger
11/24/2003	CV	Market Commentary: Market hunts for Thanksgiving deal, Ciber answers the call with small issue; trading flow low
8/15/2003	CV	Invitrogen says greenshoe exercised, raising convertibles to $350 million
7/30/2003	CV	Market Commentary: ExpressJet in holding pattern, waiting on Continental signal; three other new deals emerge
7/29/2003	CV	New Issue: Invitrogen upsized $325 million convertible yields 2.0%, up 32.5%
7/29/2003	CV	Market Commentary: ExpressJet soars in gray market, as do most of new issues in play; Nextel Partners, Dynegy emerge
7/28/2003	CV	Invitrogen $300 million quick-sale convertible talked at 1.75-2.25%, up 30-35%
7/28/2003	CV	Market Commentary: Dynegy seen launching smaller convert early Tuesday; seven other deals launched Monday
4/4/2003	CV	Market Commentary: Yahoo! overnighter meets few cheers; AES plan lifts power group; warning crushes Affymetrix
12/11/2002	CV	Market Commentary: Slow day despite new deals; Baxter gets upsized but new Navistar sinks out of the gate
9/11/2002	CV	Bear Stearns recommends Invitrogen 5.5% convertibles on heavy hedge
8/7/2002	CV	Market Commentary: Convertibles tick up along with stocks, trading spotty still but volumes gain
7/3/2002	CV	Market Commentary: Slow, choppy pre-holiday session ends higher
4/10/2002	CV	Market Commentary: Duane Reade brings new deal in new structure; Biotechs, drugs higher on short covering
4/10/2002	CV	JPMorgan recommends 9 biotech convertibles for yield, capital appreciation, relative value
3/21/2002	CV	Convertibles gain as buyers emerge, PDLI clips slide
2/28/2002	CV	Market Commentary: Convertibles choppy, lower but GM deal upped to $3.25 billion
1/16/2002	CV	Bear Stearns recommends new Invitrogen convertible on cheapening
12/7/2001	CV	Market Commentary: Convertible market slides as stock enthusiasm withers, no new deals
12/6/2001	CV	Market Commentary: Convertible market slips on thwarted rally in stocks; new issues mixed
12/6/2001	CV	New Issue: Invitrogen upsized $500 million convertibles at 2.25% yield, up 32.5%
12/5/2001	CV	Market Commentary: Convertible market roars higher as stocks rally, new deals surge

©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.